CA2902565C - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases Download PDF

Info

Publication number
CA2902565C
CA2902565C CA2902565A CA2902565A CA2902565C CA 2902565 C CA2902565 C CA 2902565C CA 2902565 A CA2902565 A CA 2902565A CA 2902565 A CA2902565 A CA 2902565A CA 2902565 C CA2902565 C CA 2902565C
Authority
CA
Canada
Prior art keywords
composition
polynucleotide
alopecia
hair
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902565A
Other languages
English (en)
French (fr)
Other versions
CA2902565A1 (en
Inventor
Alan P. Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University filed Critical Loma Linda University
Publication of CA2902565A1 publication Critical patent/CA2902565A1/en
Application granted granted Critical
Publication of CA2902565C publication Critical patent/CA2902565C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
CA2902565A 2013-03-15 2014-03-14 Treatment of autoimmune diseases Active CA2902565C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800354P 2013-03-15 2013-03-15
US61/800,354 2013-03-15
PCT/US2014/029685 WO2014145042A1 (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
CA2902565A1 CA2902565A1 (en) 2014-09-18
CA2902565C true CA2902565C (en) 2022-11-29

Family

ID=51537869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902565A Active CA2902565C (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases

Country Status (8)

Country Link
EP (1) EP2968606B1 (cg-RX-API-DMAC7.html)
JP (3) JP6499155B2 (cg-RX-API-DMAC7.html)
CN (2) CN105451777A (cg-RX-API-DMAC7.html)
AU (2) AU2014233428B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902565C (cg-RX-API-DMAC7.html)
DK (1) DK2968606T3 (cg-RX-API-DMAC7.html)
ES (1) ES2825078T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014145042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
WO2013044177A2 (en) 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗
US20180345047A1 (en) * 2015-02-26 2018-12-06 Yeda Research And Development Co. Ltd. Method of promoting hair growth

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
WO2000045823A1 (en) 1999-02-08 2000-08-10 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
JP2008538716A (ja) * 2005-04-25 2008-11-06 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 超音波トランスデューサシステムにより連続撮像するための方法及び装置
US20090191218A1 (en) * 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
WO2006124375A2 (en) * 2005-05-11 2006-11-23 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
AU2009223148B2 (en) * 2008-03-12 2013-03-14 Loma Linda University DNA vaccines and methods for the prevention of transplantation rejection
WO2011109529A1 (en) 2010-03-03 2011-09-09 Zymo Research Corporation Detection of dna methylation
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗

Also Published As

Publication number Publication date
EP2968606A1 (en) 2016-01-20
CN105451777A (zh) 2016-03-30
JP2016516725A (ja) 2016-06-09
JP6499155B2 (ja) 2019-04-10
ES2825078T3 (es) 2021-05-14
JP2021091742A (ja) 2021-06-17
AU2014233428B2 (en) 2019-09-19
CA2902565A1 (en) 2014-09-18
DK2968606T3 (da) 2020-10-26
AU2019219835A1 (en) 2019-09-12
EP2968606A4 (en) 2016-10-12
WO2014145042A1 (en) 2014-09-18
HK1220127A1 (en) 2017-04-28
EP2968606B1 (en) 2020-10-07
AU2014233428A1 (en) 2015-09-17
CN110237270A (zh) 2019-09-17
JP2019077715A (ja) 2019-05-23
AU2019219835B2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2019219835B2 (en) Treatment of autoimmune diseases
CN1759122B (zh) 包含mda-7的组合物和方法
US20040009939A1 (en) Methods of enhancing immune induction involving MDA-7
US20160375091A1 (en) Composition for Treating Prostate Cancer
CN104271147A (zh) 细胞穿膜肽
US20150202248A1 (en) E2f as a target of hormone refractory prostate cancer
JP2003516931A (ja) ペプチド作成の方法
JP6169607B2 (ja) 抗腫瘍アジュバント療法
CA2570017A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US20240043866A1 (en) Treatment of autoimmune diseases
HK1220127B (en) Treatment of autoimmune diseases
US20170204160A1 (en) Use of hdl-related molecules to treat and prevent proinflammatory conditions
HK40013739A (en) Treatment of autoimmune diseases
WO2015092756A1 (en) Recombinant fusion protein prostat and uses thereof
EP3116538A1 (en) Respiratory syncytial virus (rsv) replication inhibitors
CA2557326A1 (en) Combination of ad-p53 and chemotherapy for the treatment of tumours
WO2025217401A1 (en) A peptide inhibitor of the eya and pp2a-b55a interaction useful for myc-driven cancer therapy
CN115490763A (zh) Lum的表位肽及所述表位肽与热休克蛋白的复合物
AU2023343598A1 (en) Compositions and methods for treating cancer
Class et al. Patent application title: USE OF A TRUNCATED EIF-5A1 POLYNUCLEOTIDE TO INDUCE APOPTOSIS IN CANCER CELLS Inventors: John E. Thompson (Waterloo, CA) Zhong Sun (Waterloo, CA) Catherine Taylor (Waterloo, CA) Catherine Taylor (Waterloo, CA) Richard Dondero (Riverdale, NJ, US) Zhenyu Cheng (Waterloo, CA)
JPWO1997046676A1 (ja) 腫瘍抗原タンパク質、その遺伝子および腫瘍抗原ペプチド
HK1180218B (en) Methods and compositions involving mda-7

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240909

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240909

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504